About the Company
We do not have any company description for Cyclo Therapeutics, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Cyclo Therapeutics, Inc.
Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter ...
Investor Contact: Cyclo Therapeutics, Inc. JTC Team, LLC Jenene Thomas (833) 475-8247 CYTH@jtcir.com Applied Molecular Transport Inc. Wheelhouse Life Science Advisors Alexandra Santos asantos ...
Cyclo Therapeutics Inc. Announces Positive Safety Profile of ... - Nasdaq
Cyclo Therapeutics, Inc. met with FDA in the February 2020 to discuss the design of the Phase III global pivotal trial and expects to meet with EMA for the same purpose in the second quarter of 2020.
Cyclo Therapeutics Announces Closing of Strategic Investment Through a ...
Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL) May 02, 2023 08:12 AM Eastern Daylight Time ...
2023-12-27 | NDAQ:CYTH | Press Release | Cyclo Therapeutics Inc
Cash runway extended into 2H 2024 with approximately $11.0 million cash on hand to fund operations Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the ...
What Can We Learn About Cyclo Therapeutics' (NASDAQ:CYTH) CEO Compensation?
At the time of writing, our data shows that Cyclo Therapeutics, Inc. has a market capitalization of US$17m, and reported total annual CEO compensation of US$490k for the year to December 2019.
Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger ...
Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and ...
Is Cyclo Therapeutics, Inc. (CYTH) the Best Micro Cap Stock to Buy Now?
Cyclo Therapeutics, Inc. (NASDAQ:CYTH) is a clinical-stage biotechnology company, thriving to develop life-changing medicines aimed at patients with challenging diseases.
Cyclo Therapeutics, Inc. (CYTH) latest stock news and headlines ...
Cyclo Therapeutics to Present at the 21st Annual WORLDSymposium™ 2025 GAINESVILLE, Fla., January 14, 2025--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical ...
Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter ...
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing transformative therapies for rare and neurological diseases with limited treatment options.
Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger ...
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with disease.
Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter ...
GAINESVILLE, Fla. & SOUTH SAN FRANCISCO, Calif.-- (BUSINESS WIRE)-- Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company focused on ...
Similar Companies
Loading the latest forecasts...